Header cover image

Swedish (OMX) Pharma Industry Analysis

UpdatedJan 24, 2022
DataAggregated Company Financials
Companies43
  • 7D-3.9%
  • 3M-13.0%
  • 1Y-8.9%
  • YTD-15.6%

Over the last 7 days, the Pharma industry has dropped 3.9%, driven by a decline by Swedencare of 7.6%. Meanwhile, Infant Bacterial Therapeutics actually outperformed within the industry, gaining 12% in the last week. However, the industry is down 8.9% over the past year.

Industry Valuation and Performance

Has the Swedish Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Mon, 24 Jan 2022kr49.1bkr5.5b-kr1,083,939,448.00112.1x
Wed, 22 Dec 2021kr55.2bkr5.5b-kr1,100,338,740.00112.9x
Fri, 19 Nov 2021kr59.3bkr5.3b-kr1,355,585,770.0088x
Sun, 17 Oct 2021kr52.9bkr4.8b-kr1,581,702,061.00140.1x
Tue, 14 Sep 2021kr57.5bkr4.8b-kr1,560,489,765.26153.5x
Thu, 12 Aug 2021kr55.4bkr4.8b-kr1,412,039,942.26162.8x
Mon, 07 Jun 2021kr53.2bkr4.6b-kr1,469,283,209.50173.3x
Sun, 28 Feb 2021kr51.4bkr4.5b-kr1,418,962,725.57160.1x
Wed, 02 Dec 2020kr51.0bkr4.4b-kr913,043,309.1781.6x
Sat, 05 Sep 2020kr45.6bkr4.1b-kr535,762,892.6326x
Tue, 09 Jun 2020kr35.5bkr3.7b-kr414,746,201.6228.4x
Mon, 02 Mar 2020kr28.3bkr3.3b-kr382,446,640.8422.7x
Thu, 05 Dec 2019kr27.4bkr3.0b-kr628,422,177.0040.6x
Sun, 08 Sep 2019kr25.2bkr2.9b-kr521,071,289.0031.8x
Sat, 01 Jun 2019kr26.1bkr3.3bkr13.0m14.8x
Tue, 05 Mar 2019kr23.9bkr2.6b-kr83,038,134.0015.2x
PE Ratio

16.1x

Total Market Cap: kr23.7bTotal Earnings: -kr83,038,134.00Total Revenue: kr2.6b0%0%0%3 Year10 Year
202020212022

Current Industry PE: Investors are more optimistic on the industry, considering it's trading at a PE ratio of 112x which is higher than its 3-year average PE of 73.5x. It appears they are confident that earnings will grow faster in the future than they have historically.

Past Earnings Growth: The earnings for companies in the Pharmaceuticals industry have deteriorated over the last three years, while revenues for these companies have grown 27% per year. This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Pharma industry?

Pharma-3.89%

Industry PE: Investors are most optimistic about the Pharma industry which is trading above its 3-year average PE ratio of 73.5x. This is likely because analysts are expecting annual earnings growth of 27%, which is higher than its past year's earnings decline of 26% per year.

Forecasted Growth: Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 27% over the next 5 years. This is better than its past earnings decline of 26% per year.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
IBT B Infant Bacterial Therapeuticskr64.1012.5%
+kr79.7m
-51.1%PB1.7x
PILA PILA PHARMAkr6.5012.3%
+kr11.4m
n/aPB2.9x
LIPUM Lipumkr20.504.1%
+kr4.0m
n/aPB1.8x
ODI ODI Pharmakr5.101.2%
+kr913.2k
-0.6%PB5.1x
FOLLI Follicumkr0.352.9%
+kr817.0k
-89.3%PS61.2x
Simply Wall St
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

ENZY

kr5.78

Enzymatica

7D

-15.9%

1Y

-72.2%

FOLLI

kr0.35

Follicum

7D

2.9%

1Y

-89.3%